79344182 - BIOTHEUS

Information

  • Trademark
  • 79344182
  • Serial Number
    79344182
  • Registration Number
    7209518
  • Filing Date
    April 14, 2022
    2 years ago
  • Registration Date
    November 07, 2023
    a year ago
  • Transaction Date
    March 04, 2024
    10 months ago
  • Status Date
    November 07, 2023
    a year ago
  • Published for Opposition Date
    August 22, 2023
    a year ago
  • Location Date
    November 07, 2023
    a year ago
  • Status Code
    700
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    HUDSON, TAMARA BREE
  • Attorney Docket Number
    0579-0863US1
    Attorney Name
    Michael T. Smith
    Law Office Assigned Location Code
    L40
  • Owners
Mark Drawing Code
3000
Mark Identification
BIOTHEUS
Case File Statements
  • DM0000: The mark consists of the wording "BIOTHEUS" in stylized font above seven Chinese characters positioned horizontally; to the right of the literal element is the stylized depiction of six curving lines of varying sizes surrounding a single shaded dot.
  • GS0051: Medicines used for treating cancers; biological preparations used for treating cancer; anti-cancer pharmaceutical preparations; medicines for human purposes for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; pharmaceutical preparations for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; chemico-pharmaceutical preparations for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; medicines for medical purposes for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; chemical preparations for pharmaceutical purposes for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; biological preparations for medical purposes for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; biochemicial medicines for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; medicines in the form of injections for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases
  • TLIT00: The transliteration of the non-Latin characters in the mark is "PU MI SI SHENG WU JI SHU" wherein the word "PU" means "GENERAL," the word "MI" means "METER," the word "SI" means "THIS," and the wording "SHENG WU JI SHU" means "BIOTECHNOLOGY" in English, and the combination of Chinese characters as a whole has no meaning.
  • D10000: THE CHINESE CHARACTERS WHICH TRANSLITERATE TO "SHENG WU JI SHU"
  • GS0421: Scientific research in the field of medication evaluation; quality control evaluation for others; scientific research in the nature of conducting clinical trials for others; scientific research in the field of antibody; services of medical laboratory
Case File Event Statements
  • 3/4/2024 - 10 months ago
    26 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO
  • 2/8/2024 - 10 months ago
    25 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS
  • 2/8/2024 - 10 months ago
    24 - FINAL DISPOSITION PROCESSED Type: FIMP
  • 2/7/2024 - 10 months ago
    23 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR
  • 11/7/2023 - a year ago
    22 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC
  • 11/7/2023 - a year ago
    21 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 8/22/2023 - a year ago
    20 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 8/22/2023 - a year ago
    19 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 8/21/2023 - a year ago
    18 - NOTIFICATION PROCESSED BY IB Type: GPNX
  • 8/2/2023 - a year ago
    17 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 8/2/2023 - a year ago
    16 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R
  • 8/2/2023 - a year ago
    15 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 7/14/2023 - a year ago
    14 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 7/13/2023 - a year ago
    13 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 7/13/2023 - a year ago
    12 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 7/13/2023 - a year ago
    11 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 4/19/2023 - a year ago
    10 - REFUSAL PROCESSED BY IB Type: RFNT
  • 3/30/2023 - a year ago
    9 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS
  • 3/30/2023 - a year ago
    8 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 2/8/2023 - a year ago
    7 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 2/7/2023 - a year ago
    6 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 2/1/2023 - a year ago
    5 - ASSIGNED TO EXAMINER Type: DOCK
  • 9/10/2022 - 2 years ago
    4 - NEW REPRESENTATIVE AT IB RECEIVED Type: NREP
  • 7/12/2022 - 2 years ago
    3 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 7/8/2022 - 2 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 7/7/2022 - 2 years ago
    1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR